clearance (CrCl) levels were lower in patients assigned to EVL when compared with those assigned to mycophenolate mofetil. Further studies showed that the risk of AR was related to low EVL blood levels rather than to CsA blood levels (3) , suggesting that CsA dose could be reduced, when given in association with EVL, without compromising efficacy. In another RCT, renal transplant recipients given basiliximab, corticosteroids, and EVL (3 mg/day) were assigned to reduced-dose CsA (C0 levels between 50 and 100 ng/mL) or standard dose CsA (C0 levels between 150 and 250 ng/mL). After 3 years, the efficacy failure (AR, graft loss, death, and lost to follow-up) was significantly lower in patients receiving reduced-dose CsA (4) . Two other multicenter trials confirmed excellent 1-year graft survival and good renal function in renal transplant patients assigned to receive 1.5 or 3 mg/day of EVL in combination with reduced-dose CsA (5) .
This RCT evaluated possible differences on safety and efficacy between two regimens based on the EVL-CsA association. De novo renal transplant recipients were randomized to receive EVL at a dose targeted to maintain blood levels (C0) between 3 and 8 ng/mL and reduced-dose CsA or to receive higher doses of EVL (C0 8 -12 ng/mL) in combination with very low CsA doses.
MATERIALS AND METHODS

Study Design and Patient Population
This 6-month, prospective, open-label parallel group RCT with 12-month follow-up enrolled recipients (18 to 65 years) of single kidney transplant from a deceased or nonhuman leukocyte antigen (HLA) identical living donor, aged 14 to 65 years. The study protocol was approved by ethical committees at each participating institution. The study was conducted in compliance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines, and all patients gave informed consent in written form to study participation. Exclusion criteria were pregnancy, a current panel reactive antibody titer more than or equal to 50%, a previous transplant failed within 1 year, diagnosis of focal segmental glomerulosclerosis or primary hyperoxaluria, chronic active hepatitis, HIV positivity, plasma cholesterol levels more than or equal to 350 mg/dL (Ն9.1 mmol/dL), or triglyceride levels Ն500 mg/dL (Ն5.6 mmol/L).
Within 24 hr from graft reperfusion, patients were randomized 1:1 to the following groups:
Group A: Standard EVL؉Low-Exposure Neoral
The starting dose of EVL (Novartis Ag, Basel, Switzerland) was 0.75 mg twice daily (b.i.d.), then adjusted to reach and maintain a blood level of 3 to 8 ng/mL until the end of month 6. The initial dose of Neoral (CsA for microemulsion; Novartis Ag, Basel, Switzerland) was 2 mg/kg b.i.d., adjusted to reach a target blood level (C2) of 500 to 700 ng/mL within day 5 and to maintain the same level until the end of month 2, then slowly reduced to reach 350 to 500 ng/mL within month 6. Suggested C2 levels until month 12 were 350 to 450 ng/mL.
Group B: Upper EVL ؉ Very Low-Exposure Neoral
Upper target EVLϩvery low-exposure Neoral. As in group A, EVL was started at 0.75 mg b.i.d, and the dose adjusted to reach a blood level of 3 to 8 ng/mL in the first week. After the first week, the EVL dose was adjusted to reach a C0 of 8 to 12 ng/mL. Neoral starting dose was 2 mg/kg b.i.d., then adjusted to target a C2 level of 500 to 700 ng/mL within day 5 and until day 7; after day 8, when the EVL target levels had been reached, the CsA dose was reduced to target a C2 of 250 to 450 ng/mL by the end of month 2, then tapered to 200 to 400 by the end of month 4 and 150 to 300 ng/mL by the end of month 6. The same blood level had to be maintained until month 12.
EVL blood levels were monitored at local laboratory using the fluorescence polarization immunoassay kit (Innofluor Certican, Seradyn). All patients received basiliximab (Simulect; Novartis Ag, Basel, Switzerland) 20 mg intravenously on days 0 and 4 after transplantation, intravenous methylprednisolone (500 mg on day 0 and 40 mg on day 1), and oral prednisone (20 mg/day) in a single morning dose until day 7, then gradually tapered to a dose of 5 mg/day after day 45.
Randomization codes were generated at Novartis Farma SpA (Origgio, Varese, Italy), using a validated computer method. Each center was assigned an adequate number of sealed envelops, each of them labeled with a unique patient number, that were opened after transplantation immediately before the administration of the first EVL dose.
The core study lasted 6 months. Patients completing the core study were entered in an observational follow-up and allowed to continue the assigned treatment.
ARs were treated with intravenous methylprednisolone pulses; anti-lymphocyte antibodies were allowed for grade III rejections or steroid-resistant rejections (see definitions). Cytomegalovirus (CMV) prophylaxis was mandatory in CMVnegative recipients with CMV-positive donors. All patients received prophylactic treatment for Pneumocystis carinii pneumonia for 6 months.
Study Assessments
Efficacy
The primary outcome measures were the 6-month CrCl estimated according Cockcroft and Gault (6) and the proportion of patients with biopsy-proven acute rejection (BPAR) in either arm. The graft biopsies were examined locally according to the Banff '97 criteria (7) .
Secondary outcome measures were the proportion of patients with graft loss, death, treated ARs, antibody-treated AR, and the estimated glomerular filtration rate (GFR) according to Nankivell (8) . The presence and duration of delayed graft function (DGF), defined as a need for dialysis in the postoperative period, were also recorded.
Risk of BPAR and Blood Levels of Drugs
The correlation of the EVL and CsA blood levels with the presence of BPAR within the first 3 months after transplantation was investigated. To estimate the effect of the concentration of the drugs on the risk of BPAR, a survival analysis of EVL and CsA blood levels combinations using a Hazard model with time-dependent covariates was performed (9) .
Safety
All adverse events (AEs), serious AEs (SAEs), and all concomitant medications were recorded during the study. Hematology and serum creatinine were checked weekly in the first month and then monthly. Vital signs and biochemistry examinations were recorded at 1, 3, 6, and 12 months after transplantation.
Hypercholesterolemia was defined as a cholesterol value more than or equal to 250 mg/dL (6.41 mmol/L) and hypertriglyceridemia as a triglyceride value more than or equal to 250 mg/dL (2.80 mmol/L). New onset diabetes after transplantation was defined as a fasting serum glucose level more than 126 mg/dL and administration of insulin or oral hypoglycemic drugs in patients without diabetes at transplantation.
Statistical Methods
Assuming a common SD of 17 mL/min for CrCl, 140 patients per group were required to have 80% power of detecting a 6-month difference between groups of 6 mL/min, in favor of group B, at a 0.05 level of significance for a two-tailed test. To assess whether group B was not inferior to group A for prevention of BPAR, we hypothesized a 6-month rate of BPAR in group A of 10% to 15%, according to a previous trial (5) . The limit of noninferiority, that is, the maximum group B-group A difference, was set to 15%. For a 0.975 one-sided confidence interval, with a sample size of 140 patients per arm, the power associated with a BPAR rate in group A of 10% to 15% was always higher than 90%.
In the main analysis of CrCl, when the 6-month value was missing, the last observed value was carried forward (Last Observation Carried Foward [LOCF] method) (10), unless the patient lost the graft or died, in which case a CrCl value of "0" was imputed. A nonparametric test (Wilcoxon-Mann-Whitney) was used.
All secondary efficacy analyses were run on the Intention To Treat (ITT) population. The time to the first biopsyproven, treated or antibody-treated AR and the time to graft loss or death were analyzed by the product limit method (Kaplan-Meier). The survival curves were compared by logrank test.
Post Hoc Analysis
A post hoc analysis was conducted on the treatment compliant population, defined as patients in whom at least 50% of both CsA and EVL levels from month 2 were within the target blood levels in each group. This analysis was conducted both on the CrCl (using a LOCF) and on the GFR in patients with functioning graft.
RESULTS
Patient Characteristics and Demographics
Between May 2005 and January 2007, 285 patients were enrolled into the study before transplant surgery in 20 centers in Italy. None of the eligible patients was excluded from randomization and subsequent analysis. Only eight patients (2.8%) received a kidney from a living donor. Patient disposition is shown in Figure 1 . There were no differences between the two groups in the main donor or recipient demographic characteristics ( Table 1) .
Efficacy
Primary Endpoints
The mean 6-month CrCl in patients with functioning grafts was 59.9Ϯ18.6 mL/min in group A and 57.8Ϯ19.3 mL/ min in group B. The difference between groups was not significant, even when the LOCF approach was used (Pϭ0.7). At 12 months, the mean CrCl was 62.5Ϯ20.7 mL/min in group A versus 61.3Ϯ22.0 mL/min in group B. In this group, the recovery of CrCl after transplantation tended to be faster, although the differences with group A were never significant at any time point. The mean GFR values (Nankivell) at 6 and 12 months were, respectively, 62.3Ϯ15.6 and 64.8Ϯ17.7 mL/ min in group A in comparison with 60.0Ϯ16.4 and 63.8Ϯ18.3 mL/min in group B. (PϭNS, Fig. 2 ).
Within month 6, the BPAR event rate was 14.0% (20/ 143) in group A and 11.3% (16/142) in group B. The upper limit of the 97.5% confidence interval of the difference was 4.99% (i.e., Ͻ15%), confirming the noninferiority of group B versus group A. Kaplan Meier estimates of BPAR at 6 months are reported in Table 2 . Between 6 and 12 months, another patient in group A and four in group B developed a BPAR (PϭNS). The cumulative probability of BPAR at 1 year in groups A and B was, respectively, 14.7% and 14.1%. 
Post Hoc Analysis
The treatment compliant population comprised 107 patients in group A and 57 patients in group B. The 6-month mean values of CrCl, using the LOCF approach were, respectively, 52.9Ϯ26.2 and 58.5Ϯ23.2 mL/min in groups A and B, with a difference between groups of 5.5 mL/min in favor of group B (PϭNS). In the treatment compliant population, the probability of having a BPAR within the first 6 months were 14.9% in group A and 12.6% in group B (PϭNS).
Secondary Endpoints
Treated AR (either confirmed or not by graft biopsy) occurred in 29 patients (20.3%) of group A and in 23 patients of group B (16.2%; PϭNS) in the first 6 months and in one further patient of group A versus 6 patients of group B (Pϭ0.06) after month 6. The cumulative number of patients with rejection within month 12 was 30 (21%) in group A and 29 (20.4%) in group B. Steroid resistant AR occurred in nine patients of group A (6.3%) and in three of group B (2.1%; Pϭ0.08). There was a trend for less severe BPAR in group B: in fact, there were 11 episodes of grade II to III BPAR in group A as opposed to four in group B (Pϭ0.065, NS). Table 2 reports the 6-month estimates (Kaplan and Meier) of having a treated acute rejection or a steroid resistant acute rejection in the two groups. Ten patients of group A received a second transplant: two lost their allograft and two had a reversible, steroid-resistant AR. None of the five patients of group B who received a second transplant, lost their allograft, or had a steroid resistant AR. Of the seven group A patients with 20% to 50% anti-HLA antibodies, two lost their allograft and two had a reversible, steroid resistant AR. In group B, of the six patients with preformed anti-HLA antibodies, one lost the graft because of rejection and another patient had a reversible, steroid resistant AR. Overall, 22 study patients (7.8%) had one or more immunological risk factors. In this subgroup there were 4 graft losses (18.2%); in the remaining patients without immunological risks, the overall graft loss rate was 5.0% (13/258 The mean serum creatinine values at 6 and 12 months were, respectively, 1.56Ϯ0.52 and 1.51Ϯ0.55 mg/dL in group A and 1.63Ϯ0.59 and 1.55Ϯ0.62 in group B (PϭNS).
Graft Loss and Deaths
In group A, graft never recovered any function in four patients (2.9%). Ten other patients (7%) lost their graft, two because of renal thrombosis after recovery of graft function, two because of irreversible rejection, and one because of kidney rupture; four other patients had an AR superimposed to DGF and one was nephrectomized because of a donor-derived mycotic aneurysm. Three patients (2.1%) lost their graft in group B, respectively, because of renal vein thrombosis, renal infarction, and kidney rupture/DGF. No graft failure occurred after the sixth month.
Two patients died (1.4%) in group A, one of myocardial infarction and one of pulmonary edema. Two patients died (1.4%) in group B, respectively, from myocardial infarction and ruptured arterial mycotic aneurysm of donor origin. All deaths occurred within the sixth month.
According to ITT analysis, the 6-and 12-month deathcensored graft survival was 90.2% in group A and 97.9% in group B (Pϭ0.007). Excluding the four patients who received a nonviable kidney, the 6-month death-censored graft survival in group A was 92.8%.
Immunosuppression
The mean EVL dosage was 1.44Ϯ0.6 mg/day in group A and 2.23Ϯ1.0 mg/day in group B at 6 months; it was 1.45Ϯ0.6 and 2.31Ϯ1.0 mg/day at 12 months. The blood levels of EVL tended to remain toward the higher limit of the scheduled range in group A and toward the lower limit in group B (Fig. 3) .
The mean dosage of CsA at 6 months was 1.92Ϯ0.5 mg/kg per day in group A versus 1.56Ϯ0.6 mg/kg per day in group B; at 12 months, the mean dosages in groups A and B were, respectively, 1.74Ϯ0.5 and 1.43Ϯ0.6 mg/kg per day. The mean CsA C2 levels were within the scheduled range in group A but exceeded the upper target limit in group B, being 405.7Ϯ209 and 332.7Ϯ152 ng/mL at 6 and 12 months, respectively (Fig. 3) .
The mean prednisone daily dosages were 7.32Ϯ4.8 mg in group A and 6.2Ϯ3.2 mg in group B at 6 months and 5.09Ϯ1.8 and 5.5Ϯ4.5, respectively, at 12-month (PϭNS).
Center Effect
A post hoc analysis showed that the graft loss rate by center ranged from 0% to 18.2%, and it was 8.16% (8/98 patients) in centers including less than 14 patients in the study, as compared with 4.8% (9/187 patients) in centers including 14 patients or more. There were no significant differences between centers about the rate of BPAR or mean CrCl.
Safety
There were no differences between groups in the percentage of patients who experienced at least one AE, one SAEs or in the number of patients who discontinued study treatment due to AE (Tables 3-5 ). Although frequently reported as an AE, anemia was mainly found in the early posttransplant period and was reported as SAE in only 2.8% of the patients in group A and 2.1% in group B. Mean hemoglobin levels at 6 months were 12.6Ϯ1.5 g/dL in group A versus 12.5Ϯ1.9 g/dL in group B and tended to improve up to the twelfth month (13.0Ϯ1.5 vs. 12.8Ϯ1.6 g/dL), respectively. However, 23 patients (16.1%) in group A and 33 (23.2%) in group B were given erythropoietin as a maintenance therapy (PϭNS). Arthralgia and hypocalcemia were more frequent in group B, Urinary tract infections, dyslipidemia, pyrexia, peripheral edema, and lymphocele were other frequently reported AEs, without significant differences between groups. New onset diabetes after transplantation was diagnosed in 2.1% of patients in group A and 4.9% in group B (NS). Two patients in group B (1.4%) and one patient in group A (0.7%) developed nonmelanoma skin cancer. Infection was the most frequently reported SAE, followed by pyrexia (more frequent in group A) and lymphocele (more frequent in group B).
Overall, approximately 17% of enrolled patients stopped EVL treatment within month 6 due to AEs, mostly because of early events (nonimmunologic graft complications in group A [4.9%] and graft dysfunction in group B [2.8%]). After the sixth month, no patient in group A versus 6 in group B (PϽ0.05) had to interrupt EVL due to AEs (increased serum creatinine 2, anemia 1, edema 1, mucositis 1, proteinuria 1). One patient in group A (gum hyperpla- sia) and three patients in group B (abdominal abscess, pancreatitis, and urinary tract infection, respectively) also changed immunosuppression. Table 5 reports the AEs requiring study drug discontinuation within month 12.
Infections
The overall incidence of serious infections (requiring hospitalization) was low and similar in the two groups (10.5% in group A and 14.5% in group B, Table 4 ).
Blood Pressure
Before transplantation, 81.1% of patients in group A and 88.7% in group B were on antihypertensive treatments, that were maintained almost unchanged after transplantation. There was no difference between groups A and B in the mean number of antihypertensive medication assumed during study (2.6 vs. 2.8). In both groups, systolic blood pressure at 6 months was significantly decreased in comparison with pretransplant values (from 136Ϯ21 to 131Ϯ15 mm Hg in group A, from 140Ϯ21 to 134Ϯ17 mm Hg in group B, PϽ0.05 for both). Diastolic blood pressure was 79.1Ϯ9.0 mm Hg in group A and 80.1Ϯ9.1 mm Hg in group B at 6 months The mean levels of blood pressure at 12 months were 131Ϯ16 mm Hg or 79Ϯ9.4 mm Hg in group A versus 134Ϯ18 mm Hg and 81Ϯ11 mm Hg in group B.
Laboratory Examination
Mean plasma cholesterol levels at transplantation were 171Ϯ50 mg/dL in group A and 169Ϯ43 in group B. Cholesterol mean values were 234.9Ϯ48 mg/dL in both groups at 6 months and 231.4Ϯ40.1 versus 234.4Ϯ45.9 mg/dL at 12 months. Triglycerides levels at transplantation were 154.5Ϯ98 versus 149.5Ϯ95 mg/dL in groups A and B, 220.4Ϯ118 versus 236.0Ϯ131 mg/dL at 6 months, and 195.4Ϯ93 versus 224.0Ϯ115 mg/dL at 12 months. Statins were administered in 45.1% and 60.6% of patients in groups A and B, respectively.
There were only small changes in the mean values of leukocytes and platelets during study (data not shown).
Drug Blood Levels/BPAR Relationship
Most ARs occurred within the first 3 months after transplantation. The mean C0 EVL and C2 CsA blood levels at day 7, month 1, and month 3 were, respectively, 6.1, 8.1, and 8.2 ng/mL and 734, 631, and 511 ng/mL. Overall, the incidence of BPAR in 
DISCUSSION
A major challenge in renal transplantation is the avoidance of calcineurin inhibitors (CNIs). A few controlled trials evaluated the use of CNI-free regimens (11) (12) (13) (14) , but increased rates of AEs (13) or rejection (14) were reported. Some investigators warned that CNI should not be abandoned (15, 16) , but there is no doubt that a minimization in their dosage is desirable to reduce the CNI-related morbidity. In this regard, the synergistic interaction between CsA and EVL can provide the rationale to reduce the doses of CsA (17) . The efficacy of EVL combined with low doses of CsA in renal transplantation has been confirmed (4, 5), but the optimal dosage of CsA and EVL when given in combination is still unknown. Aim of this trial was to elucidate whether there was a difference between a regimen based on the association of low-dose CsA with standard exposure to EVL or a regimen based on even lower doses of CsA combined with higher exposure to EVL.
The cumulative mortality was low (1.4%) and was mainly caused by cardiac events that occurred in patients with preexisting risk factors. The graft survival was significantly better in group B, with only three failures, than in group A (14 graft losses). Vascular thrombosis or kidney rupture was the cause of graft loss in 6 of 281 patients (2.1%), a rate compatible with the 2% to 7% reported in adult renal transplant (18) . The cumulative graft survival censored for death, including the four patients who received a graft that never functioned (94.1%), was similar to the graft survival (91.9 -96.4) reported in RCT recently published (14, 19) , despite the relevant number of patients with immunological risk factors (7.8%) and the high proportion of deceased donors (97%) in our series.
It is interesting to note that in our study, the rate of graft loss seemed to be larger in centers that included a lower number of patients. This is in agreement with the observation that centers with low volume kidney transplants reports a higher incidence of graft loss when compared with high volume centers (20) .
The noninferiority in the BPAR rate of group B versus group A was achieved. However, no difference was seen in the primary outcome measure, namely CrCl. At 6 and 12 months, the mean CrCl was similar in the two groups, ranging around 60 mL/min. In the treatment compliant population, a difference of 5 mL/min in CrCl was observed in favor of group B, but this difference was not significant, possibly because of the reduced number of patients in this analysis. In group A, a higher number of patients showed DGF, and the median duration of DGF was longer, but the differences with group B were not significant.
As expected, the cumulative proportion of treated AR within 6 months (17.5%) was higher than that of BPAR (13.3%). This difference of 4.2%is comparable with differences ranging from 4.5% to 6% observed in other multicenter RCT (14, 19, 21) . No significant difference was seen in the incidence of treated or steroid-resistant AR between groups. However, there were more grade II or III rejections in group A and more patients in group A proved to be steroid resistant and had to be treated with antilymphocyte antibodies. No patient in group B lost the graft with a concomitant diagnosis of AR in comparison with six in group A (PϽ0.05).
Anemia was frequently reported, mainly in the first period after transplant, but the mean levels of hemoglobin approached the normal values at 6 and 12 months after transplantation, although approximately 20% of the patients of either group was given erythropoietin. Anemia was reported as serious in less than 3% of patients in both groups. Treatment with EVL may be associated with hyperlipemia and myelosuppression (2, 4, 5) . Also in our study, cholesterol and triglyceride levels were increased, although the mean values were at borderline levels according to National Cholesterol Education Program Guidelines (22) . However, approximately 80% of the patients took serum lipids modifying agents, mainly statins. The overall incidence of De novo hyperglycemia or diabetes was com- Adverse events (percentage of patients with AE) are listed independently from the relationship with study drug, including SAE, cancer and adverse events that required discontinuation of study or study treatment. parable with that observed in other trials using the EVL-CsA combination (2) (3) (4) .
The mean levels of systolic and diastolic blood pressure were within the normal range at 6 and 12 months, although most patients had to take antihypertensive drugs. It is possible that the low doses of CsA and steroids used in this trial favored a better control of blood pressure.
The overall incidence of lymphocele was lower than 20%, an incidence that is comparable with that observed in transplant patients not given mammalian target of rapamycin inhibitors (14, 23) and with the 7.2% to 18.6% reported in former EVL trials (2, 4, 5, 24, 25) . There was a trend for more frequent and more serious lymphocele in group B.
A limitation of this study is represented by the partial overlapping of CsA blood levels in the two groups. Most participants used doses of CsA higher than scheduled in group B, so that the differences in blood CsA C2 levels, although statistically significant, were lower than expected. This issue is frequent in studies with targeted blood levels of drugs, as recently reported in a large multicenter RCT (19) . The overlapping of CsA blood levels between the two groups possibly contributed to the lack of significance in the difference of CrCl between groups, the primary outcome measure.
Despite CsA blood levels in group B were not lowered as expected, the mean C2 blood levels at 12 months in this group are the lowest levels of CsA obtained in a large, RCT. In this group, EVL blood levels were within the target ranges up to month 6, although close to the lower limit, and then showed a decreasing trend up to the twelfth month. We observed a more frequent EVL discontinuation in group B after the sixth month. Our data seem to suggest that EVL blood levels should be reduced after the sixth month, although the higher than planned CsA blood levels might have contributed to the higher discontinuation rate after the sixth month.
In summary, this multicenter RCT conducted in a large number of centers in Italy under standard clinical settings failed to show that higher EVL blood levels in combination with very low exposure to CsA further improve CrCl 6 months after kidney transplantation; however, the combination of upper level EVL with very low-exposure to CsA showed a significantly better 1-year graft survival, low rate of BPAR, a good control of CNI related AEs, such as hypertension, diabetes, gum hyperplasia and hypertrichosis, and a low rate of serious infections.
